Kymera Therapeutics Financial Ratios
NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kymera Therapeutics ratio analysis
Kymera Therapeutics earned a net margin of -794.0% in FY 2025, down from -475.6% a year earlier. Gross margin was 0.0% compared with a median of 0.0% over the prior 3 years. Return on equity reached -19.7%, meaning Kymera Therapeutics generated -0.20 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Kymera Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Price / sales | 156.78 | 66.30 | 18.91 | 28.75 | 41.83 | 31.61 | — |
| Price / book | 3.89 | 3.74 | 3.76 | 2.75 | 6.63 | 3.79 | — |
| Gross margin | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Operating margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | -1,438.5% |
| Net margin | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | -1,405.8% |
| Free cash flow margin | -597.6% | -440.5% | -174.7% | -333.0% | -179.2% | 232.2% | 592.1% |
| Return on equity (ROE) | -19.7% | -26.8% | -37.2% | -31.6% | -21.8% | -16.1% | — |
| Return on assets (ROA) | -17.9% | -22.9% | -25.5% | -25.7% | -16.5% | -9.4% | -35.3% |
| Current ratio | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 | 2.73 | 2.69 |
| Revenue growth | -16.7% | -40.1% | 67.8% | -35.7% | 114.0% | 1,060.0% | — |